Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 438

1.

Frequency of breast cancer attributable to BRCA1 in a population-based series of American women.

Newman B, Mu H, Butler LM, Millikan RC, Moorman PG, King MC.

JAMA. 1998 Mar 25;279(12):915-21.

PMID:
9544765
2.

BRCA1 mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 years with first-degree family history.

Malone KE, Daling JR, Thompson JD, O'Brien CA, Francisco LV, Ostrander EA.

JAMA. 1998 Mar 25;279(12):922-9.

PMID:
9544766
3.

Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry.

Nanda R, Schumm LP, Cummings S, Fackenthal JD, Sveen L, Ademuyiwa F, Cobleigh M, Esserman L, Lindor NM, Neuhausen SL, Olopade OI.

JAMA. 2005 Oct 19;294(15):1925-33.

PMID:
16234499
4.

Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer.

Armstrong K, Micco E, Carney A, Stopfer J, Putt M.

JAMA. 2005 Apr 13;293(14):1729-36.

PMID:
15827311
5.

Using gene carrier probability to select high risk families for identifying germline mutations in breast cancer susceptibility genes.

Chang-Claude J, Dong J, Schmidt S, Shayeghi M, Komitowski D, Becher H, Stratton MR, Royer-Pokora B.

J Med Genet. 1998 Feb;35(2):116-21.

6.

BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing.

Shattuck-Eidens D, Oliphant A, McClure M, McBride C, Gupte J, Rubano T, Pruss D, Tavtigian SV, Teng DH, Adey N, Staebell M, Gumpper K, Lundstrom R, Hulick M, Kelly M, Holmen J, Lingenfelter B, Manley S, Fujimura F, Luce M, Ward B, Cannon-Albright L, Steele L, Offit K, Thomas A, et al.

JAMA. 1997 Oct 15;278(15):1242-50.

PMID:
9333265
7.

BRCA1 mutations in African Americans.

Panguluri RC, Brody LC, Modali R, Utley K, Adams-Campbell L, Day AA, Whitfield-Broome C, Dunston GM.

Hum Genet. 1999 Jul-Aug;105(1-2):28-31.

PMID:
10480351
8.

Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years.

Malone KE, Daling JR, Doody DR, Hsu L, Bernstein L, Coates RJ, Marchbanks PA, Simon MS, McDonald JA, Norman SA, Strom BL, Burkman RT, Ursin G, Deapen D, Weiss LK, Folger S, Madeoy JJ, Friedrichsen DM, Suter NM, Humphrey MC, Spirtas R, Ostrander EA.

Cancer Res. 2006 Aug 15;66(16):8297-308.

9.

Evidence for an ancient BRCA1 mutation in breast cancer patients of Yoruban ancestry.

Zhang B, Fackenthal JD, Niu Q, Huo D, Sveen WE, DeMarco T, Adebamowo CA, Ogundiran T, Olopade OI.

Fam Cancer. 2009;8(1):15-22. doi: 10.1007/s10689-008-9205-9. Epub 2008 Aug 5.

PMID:
18679828
10.

BRCA1 germline mutations in Indian familial breast cancer.

Valarmathi MT, A A, Deo SS, Shukla NK, Das SN.

Hum Mutat. 2003 Jan;21(1):98-9.

PMID:
12497638
11.

Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population.

Meindl A; German Consortium for Hereditary Breast and Ovarian Cancer.

Int J Cancer. 2002 Feb 1;97(4):472-80.

13.

Characteristics of BRCA1 mutations in a population-based case series of breast and ovarian cancer.

Anton-Culver H, Cohen PF, Gildea ME, Ziogas A.

Eur J Cancer. 2000 Jun;36(10):1200-8.

PMID:
10882857
15.

Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.

Rutter JL, Smith AM, Dávila MR, Sigurdson AJ, Giusti RM, Pineda MA, Doody MM, Tucker MA, Greene MH, Zhang J, Struewing JP.

Hum Mutat. 2003 Aug;22(2):121-8.

PMID:
12872252
16.

BRCA1 and BRCA2 germline mutations in Sardinian breast cancer families and their implications for genetic counseling.

Palmieri G, Palomba G, Cossu A, Pisano M, Dedola MF, Sarobba MG, Farris A, Olmeo N, Contu A, Pasca A, Satta MP, Persico I, Carboni AA, Cossu-Rocca P, Contini M, Mangion J, Stratton MR, Tanda F.

Ann Oncol. 2002 Dec;13(12):1899-907.

PMID:
12453858
17.

Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing.

Unger MA, Nathanson KL, Calzone K, Antin-Ozerkis D, Shih HA, Martin AM, Lenoir GM, Mazoyer S, Weber BL.

Am J Hum Genet. 2000 Oct;67(4):841-50. Epub 2000 Sep 7.

18.

Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.

Kuusisto KM, Bebel A, Vihinen M, Schleutker J, Sallinen SL.

Breast Cancer Res. 2011 Feb 28;13(1):R20. doi: 10.1186/bcr2832.

20.

BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer.

Couch FJ, DeShano ML, Blackwood MA, Calzone K, Stopfer J, Campeau L, Ganguly A, Rebbeck T, Weber BL.

N Engl J Med. 1997 May 15;336(20):1409-15.

Supplemental Content

Support Center